Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Eli Lilly to Acquire AtaiBeckley for $3.8 Billion, Accelerating Psychedelic Therapeutics Development for Treatment-Resistant Depression

Fineline Cube Jul 17, 2026
Company Deals

Jasper Therapeutics Completes Acquisition of Kira Pharmaceuticals in All-Stock Transaction, Secures $132M Private Placement for Complement Therapies Pipeline

Fineline Cube Jul 17, 2026
Company Deals

China Resources Pharmaceutical to Acquire 23.5% Stake in Lier Chemical to Advance Synthetic Biology Pipeline

Fineline Cube Jul 16, 2026
Company Deals

Braveheart Bio Files IPO Prospectus with Nasdaq for $1.8B Cardiac Myosin Inhibitor Asset

Fineline Cube Jul 16, 2026
Company Deals

WuXi Biologics Enters CDRMO Partnership with CANbridge Through 2028

Fineline Cube Jul 16, 2026
Policy / Regulatory

China’s CDE Releases Draft Guideline for Real-World Evidence-Based Pediatric Indication Expansion of Marketed Drugs

Fineline Cube Jul 16, 2026
Company Drug

Hengrui’s HRS9531 Dual GIPR/GLP-1R Agonist Advances to Phase III for Obesity with Knee Osteoarthritis, Expanding Metabolic Disease Portfolio

Fineline Cube Jul 17, 2026
Company Drug

Sichuan Biokin’s Yizekang Receives NMPA Approval as World’s First EGFR×HER3 Bispecific ADC for Esophageal Squamous Cell Carcinoma

Fineline Cube Jul 17, 2026
Company Drug

Eisai and Biogen Win EU Approval for Leqembi in Early Alzheimer’s Disease

Fineline Cube Apr 17, 2025

Eisai Co., Ltd. (TYO: 4523) and Biogen Inc. (NASDAQ: BIIB) jointly announced that they have...

Company

Jiangsu Wuzhong Pharma Faces Forced Delisting After CSRC Investigation

Fineline Cube Apr 17, 2025

China-based Jiangsu Wuzhong Pharmaceutical Group Corp. (SHA: 600200) has disclosed a potential forced delisting from...

Company Drug

Sichuan Biokin’s BL-M09D1 ADC Receives NMPA Clinical Trial Clearance for Solid Tumors

Fineline Cube Apr 17, 2025

Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506) has announced that its antibody-drug conjugate (ADC) BL-M09D1...

Company Deals

Da Ren Tang Sells Stake in Tianjin Shike to Haleon for RMB 1.623 Billion

Fineline Cube Apr 17, 2025

Tianjin Pharmaceutical Da Ren Tang Group Co., Ltd. (SHA: 600329), a traditional Chinese medicine (TCM)...

Company Deals Drug

Akeso Biopharma Partners with Virogin to Test Ivonescimab and VG201 in Colorectal Cancer Trial

Fineline Cube Apr 17, 2025

China-based Akeso Biopharma (HKG: 9926) has entered into a clinical collaboration with Virogin Biotech Co.,...

Company Deals

Berry Genomics Collaborates with Beijing Children’s Hospital on Newborn Birth Defects Screening Project

Fineline Cube Apr 17, 2025

China-based genomics testing company Berry Genomics (SHE: 000710) has entered into a project achievement translation...

Policy / Regulatory

Trump Orders HHS to Reduce Drug Prices, Revamp Medicare Negotiation Program

Fineline Cube Apr 17, 2025

President Donald Trump issued a new Executive Order aimed at reducing drug prices for American...

Company Drug

Galderma Launches Sculptra in China as First Regenerative Biostimulator

Fineline Cube Apr 16, 2025

Switzerland-based skin care specialist Galderma officially launched Sculptra in China this week, marking the first...

Company Drug

Easton Pharma’s EP-9001A Shows Promising Results in Phase Ib for Bone Metastasis Cancer Pain

Fineline Cube Apr 16, 2025

Chengdu-based Easton Pharmaceutical Co., Ltd (SHA: 688513) has announced preliminary statistical analysis results from the...

Company Medical Device

Edwards Lifesciences Gains EU CE Mark for SAPIEN M3 Mitral Valve System

Fineline Cube Apr 16, 2025

US medical device giant Edwards Lifesciences Corporation (NYSE: EW) has announced that it has received...

Company Drug

InnoCare Pharma’s Zurletrectinib NDA Accepted by China’s CDE for TRK Fusion Cancers

Fineline Cube Apr 16, 2025

Beijing-based biopharmaceutical company InnoCare Pharma (HKG: 9969, SHA: 688428) has announced that China’s Center for...

Policy / Regulatory

NHC Releases Standardized Family Doctor Service Packages for Key Demographic Groups

Fineline Cube Apr 16, 2025

The National Health Commission (NHC) has issued the “List of Basic Service Packages for Family...

Company Deals Medical Device

Kosell Medtech Partners with Wenzhou Medical University on K-Sheath System

Fineline Cube Apr 16, 2025

China-based Kossel Medtech (Suzhou) Co., Ltd., a vascular interventional medical device platform company, has entered...

Company Drug

Sichuan Biokin Secures Four Phase II Approvals for BL-B01D1 in Combination Therapies

Fineline Cube Apr 16, 2025

China-based Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506) has announced that it has secured four...

Company Drug

Hansoh Pharmaceutical Gains Clinical Approval for KRAS G12D Targeted Drug HS-10529

Fineline Cube Apr 16, 2025

China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) has announced that it has received clinical...

Company Drug

AccurEdit Therapeutics Reports Positive 24-Week Data for ART002 in HeFH Patients

Fineline Cube Apr 16, 2025

Suzhou-based gene editing specialist AccurEdit Therapeutics has announced the completion of a 24-week follow-up for...

Company Deals

Cyprumed Signs Non-Exclusive License Agreement with MSD for Oral Peptide Delivery Tech

Fineline Cube Apr 16, 2025

Germany-based Cyprumed GmbH has entered into a non-exclusive license and option agreement with Merck, Sharp...

Company Drug Policy / Regulatory

US Commerce Department Launches Section 232 Probe on Pharma Imports and National Security

Fineline Cube Apr 16, 2025

The US Department of Commerce (DoC) has initiated a Section 232 investigation to evaluate the...

Company

Johnson & Johnson Reports Q1 2025 Revenue Growth, Led by Innovative Medicines and MedTech

Fineline Cube Apr 16, 2025

US pharmaceutical giant Johnson & Johnson (J&J, NYSE: JNJ) reported Q1 2025 revenues of USD...

Company Drug

BMS Faces Phase III Setback for Camzyos in Non-Obstructive HCM Study

Fineline Cube Apr 15, 2025

US pharmaceutical giant Bristol-Myers Squibb (BMS; NYSE: BMY) has reported a setback in the Phase...

Posts pagination

1 … 207 208 209 … 696

Recent updates

  • Abbott Reports Strong Q2 2026 Results with 12.2% Revenue Growth Driven by Diagnostics Surge and Medical Device Innovation
  • Hengrui’s HRS9531 Dual GIPR/GLP-1R Agonist Advances to Phase III for Obesity with Knee Osteoarthritis, Expanding Metabolic Disease Portfolio
  • Sichuan Biokin’s Yizekang Receives NMPA Approval as World’s First EGFR×HER3 Bispecific ADC for Esophageal Squamous Cell Carcinoma
  • Eli Lilly to Acquire AtaiBeckley for $3.8 Billion, Accelerating Psychedelic Therapeutics Development for Treatment-Resistant Depression
  • Novartis’ Fabhalta Receives FDA Approval as First Oral Complement Factor B Inhibitor to Slow Renal Decline in Primary IgA Nephropathy
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company

Abbott Reports Strong Q2 2026 Results with 12.2% Revenue Growth Driven by Diagnostics Surge and Medical Device Innovation

Company Drug

Hengrui’s HRS9531 Dual GIPR/GLP-1R Agonist Advances to Phase III for Obesity with Knee Osteoarthritis, Expanding Metabolic Disease Portfolio

Company Drug

Sichuan Biokin’s Yizekang Receives NMPA Approval as World’s First EGFR×HER3 Bispecific ADC for Esophageal Squamous Cell Carcinoma

Company Deals

Eli Lilly to Acquire AtaiBeckley for $3.8 Billion, Accelerating Psychedelic Therapeutics Development for Treatment-Resistant Depression

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.